A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

By R. Kyle, Terry M. Therneau, S. Rajkumar, J. Offord, D. Larson, M. Plevak, L. Melton. New England Journal of Medicine, 2002

1,409 citations recorded by the source corpus.

Subfields: Hematology

View Paper: https://www.semanticscholar.org/paper/37d0cfae97d4a81c5d2122be33d9b2948e8af329

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

Citations in the corpus

• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009, background): “Patients with MGUS have a small risk of progression (1% per year) to MM and require only observation.(22-24) In some individuals, an intervening phase of smoldering MM (SMM) can be identified, which is characterized by a higher burden of malignant plasma cells and higher levels of monoclonal protein”
• Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “MGUS progresses to multiple myeloma or related malignancy at a rate of 1% per year.(17,18) Since MGUS is asymptomatic, over 50% of individuals who are diagnosed with MGUS have had the condition for over 10 years prior to the clinical diagnosis.”
• Advances in biology of multiple myeloma: clinical applications. (2004, background): “8,26 Mutually exclusive activating mutations of K- or N-Ras (or FGFR3 when there is a t(4;14) translocation) are rare or absent in MGUS, whereas Ras mutations are present in 30% to 40% of early MM, and FGFR3 mutations occur more frequently in advanced MM.”
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003, background): “In addition, the presence of small amounts of monoclonal light chain in the urine did not predict progression (Kyle et al, 2002).”
• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (2005, background): “The presence of a monoclonal gammopathy should not be used as the only evidence of AL, because a small fraction of patients with familial (AF), secondary (AA), and senile systemic amyloidosis (SSA) will have an incidental monoclonal gammopathy [35] and evidence of clonal plasma cell dyscrasia associ”
• Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “And, MGUS progresses to multiple myeloma or related malignancy at a rate of 1% per year.(15,16) Note, MGUS is asymptomatic, and over 50% of individuals”
• Multiple myeloma (2017, background): “Increased occurrence of del(17p) and translocation t(8;14), linking the IGH enhancer on chromo some 14 with the MYC oncogene, is clearly associ ated with progression from newly diagnosed multiple myeloma to refractory disease and plasma cell leukaemia.”